/2016

Forge Therapeutics and Evotec Form Strategic ‘Superbug’ Alliance – Combination of leading innovative chemistry efforts with cutting edge anti-infective drug discovery platform –

San Diego, Calif., December 9, 2016 – Forge Therapeutics, Inc. today announced a strategic alliance with Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, [...]

2017-10-10T16:05:19+00:00December 9th, 2016|

Forge Therapeutics Adds Superbug Experts Drs Brad Spellberg and Andrew Tomaras to Leading Antibiotic Advisory Team

San Diego, Calif., September 12, 2016 – Forge Therapeutics, Inc. announced the additions of Dr. Brad Spellberg, M.D., Chief Medical Officer of Los [...]

2017-10-09T22:06:55+00:00September 9th, 2016|

Forge Therapeutics Presenting ‘Superbug’ Program at World Anti-Microbial Resistance Congress and Harvard Anti-Infectives Rx Conference

San Diego, Calif., September 7, 2016 – Forge Therapeutics, Inc., announced presentations on its lead program targeting LpxC with novel chemistry to combat [...]

2017-10-09T17:21:04+00:00September 6th, 2016|
Load More Posts